bioAffinity Technologies, Inc. (BIAFW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
애널리스트 추정 주당순이익(EPS) $-20.70 및 매출 $0.01B 다음 회계연도.
주당순이익(EPS) 실적 추이: 2024: 실적 $-0.73 vs 추정 $-20.70 (상회 +96.5%). 2025: 실적 $-8.66 vs 추정 $-14.40 (상회 +39.9%). 애널리스트 정확도: 0%.
EPS 전망 — BIAFW
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.73
vs Est –$20.70
▲ 2,735.6% off
2025
Actual –$8.66
vs Est –$14.40
▲ 66.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
매출 전망 — BIAFW
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.009B
vs Est $0.010B
▼ 2.2% off
2025
Actual $0.006B
vs Est $0.006B
▲ 1.2% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
